Which HIV treatments are likely to cause Lipoatrophy?
The drugs that have been linked to Lipoatrophy are from the nucleoside and non-nucleoside classes of HIV treatments. These drugs include: • d4T (stavudine) (brand name Zerit®); • AZT (zidovudine) (brand name Retrovir®); and • DdI (didanosine) (brand name Videx®). • There is also some evidence linking Efavirenz (brand name Sustiva®) with Lipoatrophy. Some of these drugs are also contained in ‘once daily’ combination tablets (e.g. brand names Combivir®, Trizivir®, Atripla®). Protease inhibitors (PIs) are not believed to cause Lipoatrophy. Other new HIV drug classes like CCR5 inhibitors and integrase inhibitors have not been linked to Lipoatrophy to date.
